ARMR Sciences Inc.

NEW YORK, NY · Founded 2023 · CIK 0002082685 · Biotech · Private

Preventive immunological technologies targeting synthetic drug exposure

armrsciences.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$30M
1 Form D · Aug 2025
13 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$30,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1963Verastem Oncology——
1964VIRONGY BIOSCIENCES, INC.——
1965GLYCYX MOR, INC.——
1966ARMR Sciences Inc.—$30M
1967AOBiome LLC—$3.7M
1968Mersana Therapeutics—$69M
1969F-STOP, LLC—$85K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • Collin GageDirector · Executive Officer
  • Jeffrey HwangDirector
  • Nicholas JacobExecutive Officer
  • Kenneth KohnDirector
  • Shon RemichExecutive Officer
  • Denise ShullDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.